Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedBC
Bain Capital Life Sciences
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $251M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionCereVasc
Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases
$85MSeries C
Role not disclosedImperative Care
Develops treatments for patients suffering from thromboembolic disease
$100MGrowth
Role not disclosed